


## Xanthine oxidoreductase-IN-5

<b>Cat. No.:</b>	HY-151975
<b>CAS No.:</b>	1026652-90-3
<b>Molecular Formula:</b>	C <sub>17</sub> H <sub>17</sub> N <sub>5</sub> O <sub>2</sub>
<b>Molecular Weight:</b>	323.35
<b>Target:</b>	Xanthine Oxidase
<b>Pathway:</b>	Metabolic Enzyme/Protease
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	Xanthine oxidoreductase-IN-5 is an orally active xanthine oxidoreductase (XOR) inhibitor, with an IC <sub>50</sub> of 55 nM. Xanthine oxidoreductase-IN-5 can be used for the research of acute hyperuricemia <sup>[1]</sup> .	
<b>IC<sub>50</sub> &amp; Target</b>	IC <sub>50</sub> : 55 nM (xanthine oxidoreductase) <sup>[1]</sup>	
<b>In Vivo</b>	Xanthine oxidoreductase-IN-5 (compound IIIe) (5 mg/kg; p.o.) shows a uric acid-lowering effect from 5 h after administration in mice with acute hyperuricemia <sup>[1]</sup> .	
	MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	<b>Animal Model:</b>	ICR mice (18-22 g) were induced acute hyperuricemia by injection of potassium oxonate and hypoxanthine <sup>[1]</sup>
	<b>Dosage:</b>	5 mg/kg
	<b>Administration:</b>	Suspended in 0.5% CMC-Na solution for intragastric administration
<b>Result:</b>	Showed a uric acid-lowering effect from 5 h after administration.	

### REFERENCES

[1]. Peng W, et, al. Design, synthesis, and evaluation of tricyclic compounds containing phenyl-tetrazole as XOR inhibitors. Eur J Med Chem. 2022 Nov 28;246:114947.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA